Skip to content

Nirrin Technologies

1 viewer · 30d

Total raised

$6.7M

1 filing since 2025 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $6.7M
ROUNDS
1
INVESTORS
23
FOUNDED
N/A
HQ
Billerica, MA
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
1

AI overview

Updated

Nirrin Technologies builds analytical instruments that measure biopharmaceutical process fluids in real time. Its proprietary High-Precision Tunable Laser Spectroscopy (HPTLS) platform pairs near-infrared spectroscopy with a tunable laser source to quantify protein titer, buffers, excipients, glucose, lactate and cell density directly, without dilution or sample separation. The company sells benchtop and in-line systems used from upstream process development through formulation and fill-finish. It was founded in 2018 by Bryan Hassell and is based in Billerica, Massachusetts.

What sets it apart

HPTLS delivers direct quantitative measurement rather than model-dependent chemometric prediction, needs no dilution or sample prep, and returns results in under a minute, so the same method transfers unchanged from development scale to manufacturing scale.

Funding history

1 round
Equity+2Sep 23, 2025
Form D
+$6.7M$6.7M total

Latest SEC filings

via EDGAR · CIK 0001889145
Form D · Sep 23, 2025View on EDGAR

Products

1 tracked

ATLAS

Process analytical technology instrument

A process analytical system powered by Nirrin's HPTLS platform that performs at-line, in-line and in-situ measurement of bioprocess components, reporting product titer and buffer/excipient concentrations within minutes.

  • High-Precision Tunable Laser Spectroscopy (HPTLS) measurement engine
  • At-line, in-line and in-situ deployment modes
  • Multi-analyte quantitation of proteins, buffers and excipients
  • Measures glucose, lactate, total cell density and viable cell density

Links

WebsiteLinkedInSEC EDGAR filings